Abstract:OBJECTIVE Glucocorticoid (GC) has occupied a central role in the treatment of acute lymphoblastic leukemia due to its ability to induce apoptosis in neoplastic lymphoid cells. Glucocorticoid resistance is present among 20% initial acute lymphoblastic leukemia, even 80% refractory acute lymphoblastic leukemia. Glucocorticoid resistance has been an important determinant of clinical outcome. Glucocorticoid depends on glucocorticoid receptor (GR) to induce apoptosis. Glucocorticoid receptor, a number of nuclear hormone receptor superfamily, is mediated by many signal transduction systems. The mitogen-activated protein kinases (MAPK) superfamily of serine/threonine kinases has emerged as an important component of cellular signal transduction. Four MAP kinase families, ERK, p38 MAP kinase, JNK, and ERK5, have been well characterized. p38 MAPK usually plays a role in regulating apoptosis, cell cycle arrest and cytokines production, et al. In steroid resistance patients, IL-2 combined with IL-4 can decrease glucocorticoid receptor ligand-binding affinity via p38MAPK. In human alveolar epithelial A549 cells, dexamethasone could inhibit the activation of p38MAPK. It is unclear that the effect of p38MAPK on glucocorticoid receptor function induced by dexamethasone in CEM cells. This study aimed to investigate effect of p38 mitogen-activated protein kinase on glucocorticoid receptor function induced by dexamethasone in CEM cells. METHODS Cell viability was determined by trypan blue dye exclusion. Apoptosis was evaluated by morphology and flow cytometry. Glucocorticoid receptor protein and p-p38MAPK protein were analyzed by Western Blot. RESULTS When treatment with SB203580 and dexamethasone for 24 h to 72 h, the survival percentage was increased from 62.3%, 35.5% and 11.6% to 82.8%, 54.7% and 48.1%, respectively (P < 0.01). Co-treatment with SB203580 and dexamethasone resulted in the decrease of apoptotic percentage from 26.2% to 7.1% for 36 h (P < 0.01). p38 MAPK activation was apparent at 15 min, peaked at 1 h after dexamethasone treatment, and was sustained for 6 h. The phosphorylation was still observed at 48 h. Treatment with dexamethasone at 5 micromol/L for 12, 24, 36 and 48 h resulted in increase of GR(alpha) protein to 117%, 121%, 122% and 125% respectively. Unbinding to dexamethasone, GR(alpha) is in the cytoplasm. Nuclear-to-cytoplasmic ratio of GR(alpha) is 0.27. Treatment with dexamethasone at the same concentration and time resulted in the nuclear-to-cytoplasmic ratio increase to 0.48, 0.59, 0.95, 2.16 and 4.08 respectively. Combined treatment with SB203580 and dexamethasone resulted in the nuclear-to-cytoplasmic ratio decrease from 4.08 to 0.43 for 48 h (P < 0.05). The total GR(alpha) protein was unaffected. CONCLUSIONS Expression of GR(alpha) protein is upregulated and translocated into nucleus. p38MAPK enhances GR(alpha) protein translocation into nucleus.

Interleukin-6-independent Expression of Glucocorticoid Receptor is Upregulated by Triptolide in Multiple Myeloma

Triptolide Enhances the Sensitivity of Multiple Myeloma Cells to Dexamethasone Via Micrornas.

Triptolide Inhibits Transcription Factor Nf-Kappab and Induces Apoptosis of Multiple Myeloma Cells

Modulatory Effect of Triptolide on Differentiation of Human Th17 Cells

Triptolide affects the differentiation, maturation and function of human dendritic cells.

Triptolide Down-regulates Bcr-abl Expression and Induces Apoptosis in Chronic Myelogenous Leukemia Cells

Triptolide Inhibits the Proliferation of Cells from Lymphocytic Leukemic Cell Lines in Association with Downregulation of NF-κB Activity and Mir-16-1*.

Triptolide Overcomes Dexamethasone Resistance and Enhanced PS-341-induced Apoptosis Via PI3k/Akt/NF-kappaB Pathways in Human Multiple Myeloma Cells.

[Effect of Prednisolon, Vincristine and Mitoxantrone on Glucocorticoid Receptor in HL-60 Cell Line].

[P38 Mitogen-Activated Protein Kinase Mediates Glucocorticoid Receptor Function Induced by Dexamethasone in Acute Lymphoblastic Leukemia Cells].

RNF6 Promotes Myeloma Cell Proliferation and Survival by Stabilizing and Activating Glucocorticoid Receptor

Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 expression through PI3-K/Akt and NF-κB pathways

Triptolide Suppresses T-lymphocyte Proliferation by Inhibiting Interleukin-2 Receptor Expression, but Spares Interleukin-2 Production and Mrna Expression.

Dexamethasone Enhances Programmed Cell Death 1 (PD-1) Expression During T Cell Activation: an Insight into the Optimum Application of Glucocorticoids in Anti-Cancer Therapy

Mutant glucocorticoid receptor binding elements on the interleukin-6 promoter regulate dexamethasone effects

Tristetraprolin is Involved in the Glucocorticoid-Mediated Interleukin 8 Repression

Exploring the impact of dexamethasone on gene regulation in myeloma cells

CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy

Dexamethasone inhibits pancreatic tumor growth in preclinical models: Involvement of activating glucocorticoid receptor

Characterization of Selective Glucocorticoid‐dependent Responses in a Glucocorticoid‐resistant Smooth Muscle Tumor Cell Line

Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells